CYP2C19 Polymorphisms and Smoking Status Affects Responsiveness to the Platelet P2Y12 Receptor Antagonist Clopidogrel
Cardiovascular Prevention and Pharmacotherapy · 2019
DOI: 10.36011/cpp.2019.1.e8 ↗At a glance
Journal article in Cardiovascular Prevention and Pharmacotherapy, 2019. Written by Sang Won Han and 12 co-authors. Cited 1 times so far (Crossref); 19 references. The full text is freely available (open access, CC BY-NC 4.0).
Abstract (original language)
Ebda abstract disponibbli.
Cite
APA
Han, S. W., Kim, Y., Seo, W., Yu, S., Nam, H. S., Yoon, S. S., Kim, S. H., Lee, J. Y., Lee, J. H., Hwang, Y., Lee, J., Lee, K., & Lee, K. (2019). CYP2C19 Polymorphisms and Smoking Status Affects Responsiveness to the Platelet P2Y12 Receptor Antagonist Clopidogrel. Cardiovascular Prevention and Pharmacotherapy. https://doi.org/10.36011/cpp.2019.1.e8
Vancouver
Han SW, Kim Y, Seo W, Yu S, Nam HS, Yoon SS, et al. CYP2C19 Polymorphisms and Smoking Status Affects Responsiveness to the Platelet P2Y12 Receptor Antagonist Clopidogrel. Cardiovascular Prevention and Pharmacotherapy. 2019. doi:10.36011/cpp.2019.1.e8
BibTeX
@article{Han2019,
author = {Han, Sang Won and Kim, Yong-Jae and Seo, Woo-Keun and Yu, Sungwook and Nam, Hyo Suk and Yoon, Sung Sang and Kim, Seo Hyun and Lee, Jong Yun and Lee, Jun Hong and Hwang, Yang-Ha and Lee, Jun and Lee, Kyung-A and Lee, Kyung-Yul},
title = {CYP2C19 Polymorphisms and Smoking Status Affects Responsiveness to the Platelet P2Y12 Receptor Antagonist Clopidogrel},
journal = {Cardiovascular Prevention and Pharmacotherapy},
year = {2019},
doi = {10.36011/cpp.2019.1.e8}
}
EUVIMED